Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-modified cell therapies to treat autoimmune diseases including myasthenia gravis, myositis, and juvenile dermatomyositis. The company's lead candidate, Descartes-08, is an autologous CAR-T cell therapy that uses mRNA technology designed to degrade naturally without integrating into the genome, enabling repeated dosing and outpatient administration without intensive chemotherapy pretreatment. Cartesian operates wholly-owned cGMP manufacturing capabilities and generates potential revenue through product development partnerships, including a milestone and royalty agreement for a gout therapeutic program, while advancing its clinical pipeline toward eventual commercialization of cell therapies addressing large patient populations with limited treatment options.